Post

New research · Internal Medicine
Rheumatology (Oxford, England) · 3h
ReviewRheumatology (Oxford, England) · 2026

The risk of venous thromboembolism in rheumatoid arthritis.

Tamara Vojinovic, Johan Askling, Aleksandra Antovic
Read paper
Internal MedicineReview

Rheumatoid arthritis is linked to 50-100% higher risk of venous thromboembolism.

The risk of venous thromboembolism in rheumatoid arthritis.

Tamara Vojinovic … Aleksandra Antovic
Rheumatology (Oxford, England) · 2026
Background

Rheumatoid arthritis (rheumatoid arthritis) is associated with a markedly increased risk of venous thromboembolism (venous thromboembolism), reflecting a complex interplay between chronic inflammation, immune dysregulation, and hemostatic imbalance.

50-100%
Results
50-100%
rheumatoid arthritis raises blood clot risk well above the general population
More results

Rheumatoid arthritis-specific factors such as disease activity, seropositivity, disability and treatment exposures further modify thrombotic risk; some targeted therapies may amplify the risk in a subset of patients.

More results

Despite these insights, current venous thromboembolism risk stratification and prevention strategies are extrapolated from the general population and fail to incorporate rheumatoid arthritis-specific factors.

“
Conclusion

Improved understanding of the reason(s) behind the increased venous thromboembolism risks reported with certain immune-modulatory drugs, and development of integrated clinical and biomarker-based stratification tools, are therefore both essential to enable effective thromboprophylaxis in rheumatoid arthritis.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Cohort Study
4.5 minutes
Each visual-field test averaged 4.5 minutes per eye.
Review
46.7%
nearly half of thyroid patients had Graves' disease, the most common overactive-thyroid condition
Cross-sectional
MYR 88,346.12
Average annual out-of-pocket expenditure for patients with cancer in Malaysia.
Case-control
5.4% Reduction in Odds of Neuropathy
each rise in zinc levels lowers the chance of nerve damage
Cross-sectional
SIR 9.93
risk climbs sharply when relatives cluster and clotting starts young
Cohort Study
67.8%
one-year survival was far worse than the intermediate-risk group's, roughly one in three died
Systematic Review
“Current evidence does not support universal thromboprophylaxis following ACLR.”